Inhibitory Effects of 6,8-Diprenylorobol on Endometriosis Progression in Humans by Disrupting Calcium Homeostasis and Mitochondrial Function
article
OA: gold
CC0
⤵ 6 in-corpus citations
AI-generated summary
6,8-Diprenylorobol inhibited endometriosis cell growth by disrupting calcium homeostasis and mitochondrial function, without affecting normal endometrial stromal cells.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
6,8-Diprenylorobol is a flavonoid compound extracted from Cudrania tricuspidata. It has various biological functions, such as inhibiting melanin synthesis and inducting cell death in cancerous cells. In addition, Cudrania tricuspidata is known to be effective in female diseases, and previous studies have shown anticancer effects in cervical cancer, a female reproductive disease. Outside of that, Cudrania tricuspidata has various physiological effects. However, the effect of 6,8-diprenylorobol is not well known in other benign and chronic diseases, even in endometriosis, which commonly arises in the female reproductive tract. In the present study, we determined the inhibitory effects of 6,8-diprenylorobol on the growth of endometriosis VK2/E6E7 and End1/E6E7 cells. Results indicated that 6,8-diprenylorobol suppressed cellular proliferation and increased the disruption of the cell cycle, mitochondrial membrane potential (MMP), generation of reactive oxygen species, and Ca2+ homeostasis in both endometriosis cells. However, the proliferation of normal stromal cells isolated from endometrial tissue was not altered by 6,8-diprenylorobol. The change in Ca2+ levels was estimated in fluo-4- or rhod-2-stained VK2/E6E7 and End1/E6E7 cells after the treatment of the intracellular calcium regulators 2-aminoethoxydiphenyl borate (2-APB) and ruthenium red (RUR) with 6,8-diprenylorobol. A combination of 6,8-diprenylorobol with each regulator decreased the calcium accumulation in endometriosis cells. Furthermore, Western blot analysis indicated that 6,8-diprenylorobol inactivated AKT pathways, whereas it activated P38 MAPK pathways. In addition, 6,8-diprenylorobol decreased mitochondrial respiration, leading to the reduction in ATP production in VK2/E6E7 and End1/E6E7 cells. Collectively, our results suggested that 6,8-diprenylorobol might be a potential therapeutic agent or adjuvant therapy for the management of endometriosis.
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (45)
- Activation of mammalian target of rapamycin in postmenopausal ovarian endometriosis via openalex
- Activation of mammalian target of rapamycin in postmenopausal ovarian endometriosis via openalex
- Endometriosis via openalex
- Endometriosis: pathogenesis and treatment via openalex
- Kinase signalling pathways in endometriosis: potential targets for non-hormonal therapeutics via openalex
- Mitochondria and oxidative stress in ovarian endometriosis via openalex
- Natural products: Potential lead compounds for the treatment of endometriosis via openalex
- Quercetin inhibits proliferation of endometriosis regulating cyclin D1 and its target microRNAs in vitro and in vivo via openalex
- Silibinin‐induced endoplasmic reticulum stress and mitochondrial dysfunction suppress growth of endometriotic lesions via openalex
- The mTOR/AKT Inhibitor Temsirolimus Prevents Deep Infiltrating Endometriosis in Mice via openalex
- W2063080208 via openalex
- W2066819563 via openalex
- W2094544968 via openalex
- W2145330934 via openalex
- W2147114673 via openalex
- W2148129999 via openalex
- W2163315477 via openalex
- W2296385367 via openalex
- W2309934028 via openalex
- W2415983403 via openalex
- W2512997296 via openalex
- W2523344045 via openalex
- W2565383127 via openalex
- W2738778195 via openalex
- W2914900593 via openalex
- W2942651261 via openalex
- W3018984686 via openalex
- W3042709715 via openalex
- W3080842691 via openalex
- W3108065221 via openalex
- W3109077447 via openalex
- W3117345554 via openalex
- W3153483716 via openalex
- W6645488274 via openalex
- W1550247880 via openalex
- W6698280281 via openalex
- W1965270044 via openalex
- W1980166477 via openalex
- W2010759759 via openalex
- W2018797939 via openalex
- W2032770343 via openalex
- W2047486478 via openalex
- W2052366943 via openalex
- W2055487597 via openalex
- W2057545963 via openalex
Cited by (6)
- Managing endometriosis and endometriosis-linked cardiovascular disease events/risks with simvastatin-loaded self-nanoemulsifying drug delivery system in humanised endometriotic SD rat model 2026
- Aberrant mitochondria in endometriosis: From pathogenic mechanisms to therapeutic opportunities 2026
- Mitochondrial Involvement in the Pathogenesis of Endometriosis and its Potential as Therapeutic Targets 2025
- The role of calcium homeostasis in endometriosis: a comprehensive study of multiple types of Mendelian randomization 2023
- Establishment of Immortalized Human Endometriotic Stromal Cell Line from Ectopic Lesion of a Patient with Endometriosis 2023
- Melatonin inhibits endometriosis development by disrupting mitochondrial function and regulating tiRNAs 2022
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:24:03.506079+00:00
License: CC0
· commercial use OK